Drugs / Amenamevir
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT02403635 | Apr → May 2015 | — | Maruho Europe Limited | Completed | No outcome recorded |
| Phase 1 | NCT02369172 | Feb → Apr 2015 | — | Maruho Europe Limited | Completed | No outcome recorded |
| Phase 1 | NCT02321748 | Dec 2014 → Apr 2015 | — | Maruho Europe Limited | Completed | No outcome recorded |
| Phase 1 | NCT02280421 | Oct 2014 → Jan 2015 | — | Maruho Europe Limited | Completed | No outcome recorded |
| Phase 1 | NCT02223351 | Sep → Dec 2014 | — | Maruho Europe Limited | Completed | No outcome recorded |
| Phase 1 | NCT00870441 | Mar 2009 → Apr 2010 | — | Astellas Pharma Inc | Terminated | No outcome recorded |
| Phase 1 | NCT02796118 | Jul → Oct 2006 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT02852876 | Sep → Dec 2005 | genital herpes, herpes zoster | Astellas Pharma Europe Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00487682 | Nov 2007 → Sep 2008 | herpes zoster | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT00486200 | Jun 2007 → Aug 2008 | genital herpes | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 33 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT02209324 | Nov 2013 → Jul 2015 | herpes simplex infectious disease | Maruho Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01959841 | Aug 2013 → Jul 2015 | herpes zoster | Maruho Co., Ltd. | Completed | Met primary |
| Phase 3 | NCT01959295 | Aug 2013 → Apr 2015 | herpes simplex infectious disease | Maruho Co., Ltd. | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amenamevir | “Amenamevir (ASP2151) is a nonnucleoside antiherpesvirus compound” PMID 29134426 ↗ Nov 2017 |
| Known as | ASP2151 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02796118 ↗ |
| Modality | Small molecule | “nonnucleoside antiherpesvirus compound” PMID 29134426 ↗ Nov 2017 |
| Route | Oral | “Oral administration.” NCT00486200 ↗ |